Effects of Cannabidiol on TAFAZZIN-Deficient B-Lymphoblastoid Cells

Area of Science:

• Biochemistry
• Genetics
• Immunology

Background:

• Barth Syndrome (BTHS) is an X-linked disorder affecting cardiolipin remodeling due to TAFAZZIN gene mutations.
• While cyclic neutropenia is known, BTHS may also involve lymphopenia.
• Understanding BTHS pathophysiology is crucial for therapeutic development.

Purpose of the Study:

• To investigate the effects of cannabidiol (CBD) on BTHS patient-derived B-lymphoblastoid cells.
• To assess CBD's impact on cell growth, cardiolipin metabolism, and mitochondrial function in BTHS.
• To explore CBD as a potential therapeutic for BTHS-associated lymphopenia.

Main Methods:

• Utilized BTHS patient-derived B-lymphoblastoid cell lines.
• Administered 1 μM cannabidiol (CBD) to treated cells.
• Assessed cell growth, cell cycle distribution, cardiolipin content, and mitochondrial respiration.
• Analyzed specific mitochondrial protein expression and supercomplex levels.

Main Results:

• CBD (1 μM) normalized BTHS B-lymphoblastoid cell growth.
• CBD fully restored total cardiolipin concentration and the monolysocardiolipin/cardiolipin ratio.
• CBD enhanced maximal coupled state III respiration and mitochondrial membrane potential.
• CBD improved deficits in specific mitochondrial respiratory chain subunits and supercomplexes.

Conclusions:

• Cannabidiol demonstrates therapeutic potential for Barth Syndrome by improving cellular growth and mitochondrial function.
• CBD effectively restores cardiolipin levels and key respiratory chain components in BTHS cells.
• Further investigation into CBD as a treatment for BTHS-related lymphopenia is warranted.